Malini Madhavan1, Tiffany Y Hu2, Bernard J Gersh3, Veronique L Roger4, Jill Killian5, Susan A Weston5, Jonathan Graff-Radford6, Samuel J Asirvatham3, Alanna M Chamberlain5. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: madhavan.malini@mayo.edu. 2. Department of Medicine, University of California, Los Angeles. 3. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. 4. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 6. Department of Neurology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF). PATIENTS AND METHODS: We conducted an observational population-based study of 2800 nondemented patients with incident AF from January 1, 2000, through December 31, 2010. The association of incident dementia with warfarin therapy and TTR was examined using Cox proportional hazards regression models. RESULTS: Mean patient age was 71.2 years; 53% were men (n=1495), and warfarin was prescribed to 50.5% (n=1414) within 90 days of AF diagnosis. Incident dementia diagnosis occurred in 357 patients (12.8%) over a mean ± SD follow-up of 5.0±3.7 years. After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR], 0.80; 95% CI, 0.64-0.99). However, only those in the 2 highest quartiles of TTR were associated with lower risk of dementia. A 10% increase in TTR with a 10% reduction in time spent in the subtherapeutic (HR, 0.71; 95% CI, 0.64-0.79) and supratherapeutic (HR, 0.67; 95% CI, 0.57-0.79) ranges were associated with decreased risk of dementia. CONCLUSION: In the community, warfarin therapy for AF is associated with a 20% reduction in risk of dementia. Increasing TTR on warfarin is associated with reduced risk of dementia. The risk of dementia was reduced with a reduction in time spent in subtherapeutic and supratherapeutic international normalized ratio range. Effective anticoagulation may prevent cognitive impairment in patients with AF.
OBJECTIVE: To study the association between time in therapeutic range (TTR) during warfarin therapy and risk of dementia in a population-based cohort of incident atrial fibrillation (AF). PATIENTS AND METHODS: We conducted an observational population-based study of 2800 nondemented patients with incident AF from January 1, 2000, through December 31, 2010. The association of incident dementia with warfarin therapy and TTR was examined using Cox proportional hazards regression models. RESULTS: Mean patient age was 71.2 years; 53% were men (n=1495), and warfarin was prescribed to 50.5% (n=1414) within 90 days of AF diagnosis. Incident dementia diagnosis occurred in 357 patients (12.8%) over a mean ± SD follow-up of 5.0±3.7 years. After adjusting for confounders, warfarin therapy was associated with a reduced incidence of dementia (hazard ratio [HR], 0.80; 95% CI, 0.64-0.99). However, only those in the 2 highest quartiles of TTR were associated with lower risk of dementia. A 10% increase in TTR with a 10% reduction in time spent in the subtherapeutic (HR, 0.71; 95% CI, 0.64-0.79) and supratherapeutic (HR, 0.67; 95% CI, 0.57-0.79) ranges were associated with decreased risk of dementia. CONCLUSION: In the community, warfarin therapy for AF is associated with a 20% reduction in risk of dementia. Increasing TTR on warfarin is associated with reduced risk of dementia. The risk of dementia was reduced with a reduction in time spent in subtherapeutic and supratherapeutic international normalized ratio range. Effective anticoagulation may prevent cognitive impairment in patients with AF.
Authors: Marije R Benedictus; Anaïs Hochart; Costanza Rossi; Gregoire Boulouis; Hilde Hénon; Wiesje M van der Flier; Charlotte Cordonnier Journal: Stroke Date: 2015-08-13 Impact factor: 7.914
Authors: Brenda L Plassman; Kenneth M Langa; Ryan J McCammon; Gwenith G Fisher; Guy G Potter; James R Burke; David C Steffens; Norman L Foster; Bruno Giordani; Frederick W Unverzagt; Kathleen A Welsh-Bohmer; Steven G Heeringa; David R Weir; Robert B Wallace Journal: Ann Neurol Date: 2011-03-18 Impact factor: 10.422
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: Jonathan Graff-Radford; Malini Madhavan; Prashanthi Vemuri; Alejandro A Rabinstein; Ruth H Cha; Michelle M Mielke; Kejal Kantarci; Val Lowe; Matthew L Senjem; Jeffrey L Gunter; David S Knopman; Ronald C Petersen; Clifford R Jack; Rosebud O Roberts Journal: Alzheimers Dement Date: 2015-10-23 Impact factor: 21.566
Authors: Jane S Saczynski; Saket R Sanghai; Catarina I Kiefe; Darleen Lessard; Francesca Marino; Molly E Waring; David Parish; Robert Helm; Felix Sogade; Robert Goldberg; Jerry Gurwitz; Weijia Wang; Tanya Mailhot; Benita Bamgbade; Bruce Barton; David D McManus Journal: J Am Geriatr Soc Date: 2019-10-01 Impact factor: 5.562
Authors: Adrienne Tin; Keenan A Walker; Jan Bressler; B Gwen Windham; Michael Griswold; Kevin Sullivan; Aozhou Wu; Rebecca Gottesman; Myriam Fornage; Josef Coresh; A Richey Sharrett; Aaron R Folsom; Thomas H Mosley Journal: Neuroepidemiology Date: 2021-06-02 Impact factor: 5.393